Ninety One North America 13F: New $4.5M Stake in Illumina (ILMN)

Ninety One North America established a fresh stake in Illumina, Inc. (NasdaqGS: ILMN) during the third quarter, according to a Form 13F filing filed with the Securities and Exchange Commission on October 15, 2026. The filing shows the firm purchased 16,418 shares. The reported value of the holding reached about $4.49 million. Because 13F filings look backward at holdings from the end of the quarter, this disclosure reflects portfolio choices made during that period and might not represent the firm's current share count today.

Other Institutional Activity in Illumina, Inc.

Other large institutional investors adjusted their positions in the genomics company during the filing period. Blackrock Inc. grew its holdings by 167,411 shares, ending with 19,191,398 shares worth about $5.04 billion after a 0.9% increase. Capital World Investors trimmed its stake by 124,398 shares, leaving it with 15,425,298 shares valued at roughly $4.05 billion following a 0.8% decrease. Vanguard Portfolio Management LLC reduced its position by 196,522 shares, or 2.9%, to finish with 6,627,157 shares worth about $1.74 billion. Vanguard Capital Management LLC cut its holdings slightly by 7,254 shares, or 0.1%, holding 6,587,534 shares valued at about $1.73 billion. State Street Corporation lifted its stake by 77,797 shares, representing a 1.2% increase, to own 6,507,288 shares worth roughly $1.71 billion.

Illumina, Inc. Stock Down 2.0%

Illumina shares recently traded around $262.56 as of October 16, 2026. That puts the stock about 15.1% below its 52-week high of $309.35 and well above its 52-week low of $94.00. The shares trade 12.9% above their 50-day moving average of $232.54 and 55.4% above their 200-day moving average of $169.00.

Recent Earnings

Illumina posted trailing twelve-month revenue of $4.49 billion and earnings of $5.39 per share. The company reported a net profit margin of 18.3% alongside a return on equity of 32.3%. Revenue grew 9.4% compared to the same period a year earlier. The company is scheduled to release its next financial results on October 29, 2026.

Insider Buying and Selling at Illumina, Inc.

Company insiders completed several transactions in the months leading up to the filing. Officer Christensen Jakob Wedel sold 1,033 shares on August 18, 2026, at an average price of $191.52 for a total value of $197,840. Director Keith A Meister executed three separate sales. He sold 679,574 shares valued at $145.56 million on August 21, 2026, followed by 375,941 shares worth $85.24 million on August 27, 2026, and another 263,560 shares worth $57.20 million on September 4, 2026. None of these transactions were carried out under a planned Rule 10b5-1 trading arrangement.

Analysts Set New Price Targets

Wall Street firms updated their price targets and ratings on Illumina over recent weeks. Leerink Partners maintained its outperform rating while raising its price target to $300.00 from $220.00 on September 29, 2026. Guggenheim kept a buy rating on the stock, lifting its target from $226.00 to $305.00 on October 1, 2026. RBC Capital maintained an outperform rating and bumped its target to $310.00 from $230.00 on October 5, 2026. Barclays kept its underweight rating while raising its target to $200.00 from $160.00 on October 7, 2026. TD Cowen maintained a hold rating and raised its target from $210.00 to $270.00 on October 13, 2026. Overall, the stock holds a consensus buy rating from analysts, with a mean price target of $241.05 across 20 analyst opinions.

About Illumina, Inc.

Based in San Diego, California, Illumina provides sequencing and array-based tools for genetic and genomic analysis. The company serves customers across healthcare, academic research, and applied markets globally, helping scientists study DNA and genetic variation.

Bottom Line

Ninety One North America's new stake adds to the broader institutional picture for Illumina as the company prepares for its upcoming financial report on October 29, 2026. Investors tracking these positions should keep in mind that 13F filings are historical snapshots and may not reflect current holdings.